Neuropathy News and Research

RSS

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria.

18 May 2013

Statistics reveal that about 79 million adult Americans walk around with prediabetes

Diabetes is one of the most misunderstood medical conditions. "It's not just about sugar. It's about your heart," says Nancy Ryan, RD, BC-ADM, a registered dietitian, board-certified in advanced diabetes management at Greenwich Hospital in Greenwich, Connecticut.

16 May 2013

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Lexicon Pharmaceuticals, Inc. announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial.

10 May 2013

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain is caused by lesion or disease to the peripheral somatosensory nervous system. Nerve damage that can lead to peripheral neuropathic pain can happen as a result of a range of different diseases, medications or traumatic injuries.

8 May 2013

Study: Combination of chemotherapy and nerve-protecting agents can prevent anemia

Cancer chemotherapy can cause peripheral neuropathy-nerve damage often resulting in pain and muscle weakness in the arms and legs. Now, researchers at Albert Einstein College of Medicine of Yeshiva University have discovered that chemo also induces an insidious type of nerve damage inside bone marrow that can cause delays in recovery after bone marrow transplantation.

6 May 2013

New FDA-approved method for detecting diabetic neuropathy

Details of a new method to detect diabetic neuropathy in patients in less than five minutes using their sweat glands was presented today at the American Association of Clinical Endocrinologists 22nd Annual Scientific and Clinical Congress in Phoenix, Arizona by Aaron I. Vinik, M.D., Ph.D., F.C.P., M.A.C.P., F.A.C.E., Professor of Medicine and Director of Research and the Neuroendocrine Unit at Eastern Virginia Medical School.

4 May 2013

Researchers identify how a defective protein plays central role in Giant Axonal Neuropathy

A team of international researchers led by Northwestern Medicine scientists has identified how a defective protein plays a central role in a rare, lethal childhood disease known as Giant Axonal Neuropathy, or GAN.

29 Apr 2013

New treatment strategy for patients with CMT disease on the horizon

A potential new treatment strategy for patients with Charcot-Marie-Tooth disease is on the horizon, thanks to research by neuroscientists now at the University at Buffalo's Hunter James Kelly Research Institute and their colleagues in Italy and England.

29 Apr 2013

Researchers identify how proteasome takes care of unwanted, potentially toxic proteins

Proteins, unlike diamonds, aren't forever. And when they wear out, they need to be degraded in the cell back into amino acids, where they will be recycled into new proteins.

29 Apr 2013

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

The Massachusetts General Hospital Neurological Clinical Research Institute and Prize4Life, a nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for amyotrophic lateral sclerosis, received a Best Practices Award at the 2013 Bio-IT World Conference & Expo.

15 Apr 2013

Gene variations can predispose people to chemotherapy-induced peripheral neuropathy

Seemingly benign differences in genetic code from one person to the next could influence who develops side effects to chemotherapy, a Mayo Clinic study has found.

10 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

GenSight Biologics announces closing of €32 million Series A financing

GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a €32 million Series A financing.

8 Apr 2013

Duloxetine drug alleviates pain from chemotherapy

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April 3 issue of JAMA.

3 Apr 2013

Medicare reimbursement cuts threaten access to care

Physicians and patients alike are feeling the impact of Medicare reimbursement cuts that went into effect on January 1, 2013. With an additional 2% sequestration cut to roll out on April 1, it's likely that physicians who treat Medicare patients will be faced with difficult decisions as operating margins continue to shrink.

29 Mar 2013

Inflammation and epigenetics: an interview with Dr Belkina and Dr Denis, Boston University School of Medicine

Inflammation can be thought of as taking two major forms: acute or chronic. Acute inflammation, which can be painful, usually arises quickly and resolves quickly. It accompanies bacterial infections, traumatic injury and is useful to fight infections and promote healing.

28 Mar 2013

New research sheds light on natural mechanism that protects ears from hearing loss

New research from the Massachusetts Eye and Ear, Harvard Medical School and Harvard Program in Speech and Hearing Bioscience and Technology may have discovered a key piece in the puzzle of how hearing works by identifying the role of the olivocochlear efferent system in protecting ears from hearing loss.

28 Mar 2013

Genetic testing services for rare neurological disorders launched by Athena Diagnostics

Athena Diagnostics, a leader in neurological diagnostics, today announced the clinical availability of new genetic tests to aid the detection of several rare neurological disorders, including hereditary neuropathy, neuromuscular disease, epilepsy and certain movement disorders. The lab-developed tests are available through Athena Diagnostics, a business of Quest Diagnostics (NYSE:DGX), the world’s leading provider of diagnostic information services.

From Quest Diagnostics 19 Mar 2013

Dementia diagnostic panel for treatable forms of cognitive impairment launched by Quest Diagnostics

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, announced the availability of the first clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The test panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.

From Quest Diagnostics 19 Mar 2013

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

19 Mar 2013

Neuropathy News and Research

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Statistics reveal that about 79 million adult Americans walk around with prediabetes

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Study: Combination of chemotherapy and nerve-protecting agents can prevent anemia

New FDA-approved method for detecting diabetic neuropathy

Researchers identify how a defective protein plays central role in Giant Axonal Neuropathy

New treatment strategy for patients with CMT disease on the horizon

Researchers identify how proteasome takes care of unwanted, potentially toxic proteins

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

Gene variations can predispose people to chemotherapy-induced peripheral neuropathy

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

GenSight Biologics announces closing of €32 million Series A financing

Duloxetine drug alleviates pain from chemotherapy

Medicare reimbursement cuts threaten access to care

Inflammation and epigenetics: an interview with Dr Belkina and Dr Denis, Boston University School of Medicine

New research sheds light on natural mechanism that protects ears from hearing loss

Genetic testing services for rare neurological disorders launched by Athena Diagnostics

Dementia diagnostic panel for treatable forms of cognitive impairment launched by Quest Diagnostics

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News